In the development of advanced therapeutics such as CAR-T cells, dendritic cell (DC) vaccines, and radiopharmaceuticals, understanding the spatiotemporal distribution, target engagement, and persistence of therapeutic agents in vivo is a critical component of preclinical evaluation. Conventional techniques-including histopathology and ex vivo fluorescence analysis-are inherently limited by their terminal nature and inability to provide continuous, whole-body dynamic data.
To address these limitations, non-human primate (NHP) models combined with clinical-grade PET/CT imaging have emerged as a highly translatable platform for longitudinal, quantitative, and non-invasive tracking of immune cells and molecular probes. This approach enables real-time visualization of biological processes under physiological conditions closely resembling human systems.
At Prisys Biotech, this capability is integrated into a comprehensive translational imaging platform, supporting both cell therapy evaluation and novel PET tracer development within a clinically relevant framework.
Longitudinal In Vivo Tracking of Immune Cells
A central challenge in cell therapy development is the ability to accurately characterize the in vivo kinetics of infused cells, including their biodistribution, migration, expansion, and tissue-specific homing.
Prisys Biotech employs radiolabel-based cell tracking strategies combined with high-resolution PET/CT imaging to address this need. Immune cells such as T cells or dendritic cells can be labeled ex vivo using positron-emitting isotopes, enabling sensitive and quantitative detection after re-infusion into NHP models.
One of the most widely used isotopes in this context is Zirconium-89 (⁸⁹Zr). With a physical half-life of approximately 3.27 days, ⁸⁹Zr is particularly well-suited for mid- to long-term tracking studies, allowing repeated imaging over several days without significant signal loss. Following administration, whole-body PET/CT scans can be performed at predefined time points to generate quantitative biodistribution maps.
This approach provides several key advantages:
- Enables non-terminal, longitudinal assessment of cell fate
- Supports quantitative analysis of tissue-specific accumulation (e.g., lymph nodes, spleen, bone marrow, tumor or inflammatory sites)
- Facilitates evaluation of targeting efficiency, systemic safety, and retention time
- Reduces inter-animal variability by allowing repeated measurements in the same subject
Importantly, the use of NHP models ensures that these data reflect clinically relevant immune system behavior, significantly improving the predictive value for human studies.
Development and Validation of Novel PET Tracers
Beyond tracking therapeutic cells, the same imaging platform supports the development of novel PET tracers for diagnostic and theranostic applications.
In early-stage tracer development, it is essential to evaluate:
- Target specificity and binding affinity
- In vivo stability and metabolic profile
- Whole-body distribution and clearance pathways
- Radiation dosimetry and safety
Rodent models often fail to fully capture the complexity of human physiology, particularly for tracers targeting immune, neurological, or metabolic pathways. In contrast, NHP models provide high anatomical and physiological similarity to humans, making them a critical bridge between small animal studies and clinical trials.
Prisys Biotech enables end-to-end tracer evaluation, including:
- Radiolabeling strategy development and optimization
- PET/CT imaging protocol design aligned with clinical standards
- Quantitative image analysis and kinetic modeling
- Correlation with bio-sampling data (Pharmacokinetics (PK), Pharmacodynamics (PD), biomarker analysis)
Integrated Translational Imaging Platform at Prisys Biotech
The strength of this approach lies not only in imaging technology, but in the integration of multiple translational research capabilities within a single platform.
Prisys Biotech operates a clinical-equivalent imaging infrastructure, including PET/CT, MRI, CT, and DSA systems, supported by experienced radiologists and multidisciplinary scientific teams. These capabilities enable:
- Cross-modality imaging for comprehensive evaluation of disease and therapeutic response
- Image-guided interventions, including targeted delivery and biopsy
- Quantitative endpoint definition aligned with clinical trial methodologies
In addition, the platform is embedded within a broader NHP translational research ecosystem, which includes:
- A diverse portfolio of disease models across CNS/Neurology, Immunology & Inflammation, respirology, and cardiometabolism indications
- PK/PD and bioanalytical capabilities for integrated pharmacological assessment
- Advanced technologies such as MRI-Guided Drug Delivery For CNS Research and AI-based NHP Behavior Analysis System
- Animal-Welfare (AAALAC-accredited) facilities ensuring high standards of animal welfare and regulatory compliance
Conclusion
In vivo immune cell tracking and PET tracer development represent critical components of modern drug development, particularly in the fields of immunotherapy, oncology, and precision medicine.
By combining non-human primate models with Clinical Imaging technologies, researchers can achieve:
- Direct visualization of cellular and molecular dynamics in living systems
- Quantitative, longitudinal data supporting decision-making
- Enhanced translational relevance for clinical development
Prisys Biotech provides a fully integrated platform that bridges the gap between preclinical research and clinical application, enabling more informed evaluation of therapeutic strategies and accelerating the development of next-generation diagnostics and treatments.
FAQ
Q: Why are NHP models important for immune cell tracking studies?
A: NHP models closely replicate human immune system structure and function, enabling more accurate evaluation of cell distribution, migration, and persistence compared to rodent models.
Q: What advantages does ⁸⁹Zr labeling provide in PET imaging?
A: ⁸⁹Zr has a relatively long half-life, allowing longitudinal tracking of labeled cells over several days with high sensitivity and quantitative accuracy.
Q: How does Prisys support PET tracer development?
A: Prisys provides integrated services including radiolabeling, in vivo imaging, kinetic analysis, and PK/PD correlation in NHP models, enabling efficient validation of novel diagnostic tracers.
